CYP19A1 and postmenopausal osteoporosis: Moreover, polymorphisms in estrogen metabolism-related genes, such as PDSS1, CYP19A1, CYP1A1, and CYP1B1, have been associated with varied efficacy of raloxifene, a selective estrogen receptor modulator frequently prescribed for postmenopausal osteoporosis [102].